Autolus Therapeutics plc revenue
Autolus Therapeutics plc's revenue was $75.4m in fiscal 2025, up 644.9% on the year before. Since fiscal 2016 ($1.2m) it has grown at a compound 99.1% a year. Over the last twelve months it was $117m.
Revenue history
| Fiscal year | 2016Sept 2016 | 2017Sept 2017 | 2018Sept 2018 | 2019Dec 2019 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 2 | 1 | 3 | 2 | 10 | 75 | 117 |
| Growth on the year before | — | +39.7% | −16.9% | +106.7% | −41.6% | +496.0% | +644.9% | — |
| Gross profit | — | — | — | — | 2 | −1 | −21 | 18 |
| Gross margin | — | — | — | — | 100.0% | −12.5% | −27.8% | 15.7% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $74.3M | 98.6% | — |
| Licenses | $1.1M | 1.4% | ▼ 89.4% |
From Autolus Therapeutics plc's 10-K filed March 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Autolus Therapeutics plc | $117m | 292.2% | — |
| Arcus Biosciences, Inc. | $117m | -55.3% | -1.1% |
| ARS Pharmaceuticals, Inc. | $117m | 4.1% | 711.3% |
| Mesoblast LTD | $120m | 599.2% | — |
| Xencor Inc | $105m | -28.6% | -2.5% |
| Agenus Inc | $133m | 30.5% | 10.1% |
Compare with peers
- Arcus Biosciences, Inc. revenue
- ARS Pharmaceuticals, Inc. revenue
- Mesoblast LTD revenue
- Xencor Inc revenue
- Agenus Inc revenue
Head to head: AUTL vs RCUSAUTL vs SPRYAUTL vs MESO
More: Biotechnology stocks compared, Health Care sector, rankings of US companies